REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

201885 citationsJournal Articlehybrid Open Access

Authors

The therapeutic sequence of regorafenib followed by cetuximab suggests a longer OS than the current standard sequence.

Good health and well-being

Published in: Annals of Oncology

Volume 30, Issue 2, pp. 259-265

Field-Weighted Citation Impact: 4.34